In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems

Philippe Robin 1, 2 Srishti Kumar Pierre-Yves Salaun 1, 2 Pierre-Yves Le Roux 1, 2 Francis Couturaud 3, 2 Benjamin Planquette 4, 5, 6 Adel Merah Pierre-Marie Roy 7 Kednapa Thavorn Grégoire Le Gal 2, 8
1 CHU - BREST - Med Nucléaire - CHRU Brest - Service de médecine nucléaire
2 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
3 DMIP - Brest - Département de Médecine Interne et Pneumologie [Brest]
4 IThEM - U1140 - Innovations thérapeutiques en hémostase
5 UPD5 - Université Paris Descartes - Paris 5
6 Pneumo - HEGP - Service de Pneumologie, soins intensifs
7 PMR - Service des Urgences
8 CIC Brest
Document type :
Journal articles
Complete list of metadatas
https://hal.univ-brest.fr/hal-02057877
Contributor : Ghislaine Calvez <>
Submitted on : Tuesday, March 5, 2019 - 4:23:57 PM
Last modification on : Thursday, April 11, 2019 - 4:02:54 PM

Identifiers

Collections

UNIV-BREST | GETBO | UNIV-PARIS5 | IBSAM | USPC

Citation

Philippe Robin, Srishti Kumar, Pierre-Yves Salaun, Pierre-Yves Le Roux, Francis Couturaud, et al.. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research, Elsevier, 2018, 171, pp.97-102. ⟨10.1016/j.thromres.2018.09.050⟩. ⟨hal-02057877⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

51

Contact

CCSD